

## **Pharmacy Drug Policy Checklist**

POLICY NAME Filspari (sparsentan) POLICY # 3368P

## Criteria

Coverage Criteria	
	Diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by biopsy
	Age 18 years or older
	Prescribed by or in consultation with a nephrologist (kidney doctor) in the Filspari REMS program
	eGFR ≥30 mL/min/1.73 m2
	Total urine protein ≥ 1g/day
	Previous trial and failure of one generic RAS inhibitor (such as lisinopril or losartan) at maximally tolerated dose unless contraindicated
Exclusion Criteria – Any of the following prevents coverage	
	Pregnancy
	Chronic kidney disease due to any other condition or currently receiving dialysis
	Filspari will not be approved if being used in addition to angiotensin receptor blockers (ARBs), endothelin receptor antagonists (ERAs) or aliskiren or Tarpeyo